secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0000950170-23-040611
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen Q2 net loss $9.4M; cash runway extended into 2025 on prioritization
----------------------------------------------------------------------------

- Net loss of $9.4M improved from $13.9M YoY; cash and securities $53.4M (down from $61.7M in Q1).
- R&D expenses fell to $6.9M from $9.6M YoY; G&A expenses to $3.3M from $4.5M YoY.
- SZN-043 Phase 1a enrollment continues; safety data expected by end of 2023; Phase 1b in alcoholic hepatitis planned for 2024.
- SZN-1326 Phase 1a enrollment continues; Phase 1b in ulcerative colitis planned for 2024, proof-of-concept data expected H2 2024.
- Boehringer Ingelheim partnership may trigger $10M milestone in 2024 upon Fzd-4 candidate nomination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000095017023040611/0000950170-23-040611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000095017023040611/srzn-20230809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer